Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line

Endocrine-Related Cancer

Volumn 18, Issue 1, 2011, Pages 113-127

  Karmakar, Sudipan ^a   Foster, Estrella A ^a   Blackmore, Julia K ^a   Smith, Carolyn L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; LUCIFERASE; NUCLEAR RECEPTOR COACTIVATOR 2; SMALL INTERFERING RNA; STEROID RECEPTOR COACTIVATOR 1; STEROID RECEPTOR COACTIVATOR 3;

APOPTOSIS; ARTICLE; BASAL CELL; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE SILENCING; PROTEIN DEPLETION; REPORTER GENE;

BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; MULTIGENE FAMILY; NUCLEAR RECEPTOR COACTIVATOR 3; NUCLEAR RECEPTOR COACTIVATORS; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION;

EID: 79251486359     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0285     Document Type: Article

References (39)

1. Al-Dhaheri MH & Rowan BG 2006 Protein kinase A exhibits selective modulation of estradiol dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction and changes in receptor phosphorylation. Molecular Endocrinology 21 439-456. (doi:10.1210/me.2006-0059)
2. Amazit L, Pasini L, Szafran AT, Berno V, Wu RC, Mielke M, Jones ED, Mancini MG, Hinojos CA, O'Malley BW et al. 2007 Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Molecular and Cellular Biology 27 6913-6932. (doi:10.1128/MCB.01695-06)
3. Arteaga CL, Koli KM, Dugger TC & Clarke R 1999 Reversal of tamoxifen resistance of human breast carcinomas in vivo by neuralizing antibodies to transforming growth factor-β. Journal of the National Cancer Institute 91 46-53. (doi:10.1093/jnci/91.1.46)
4. Brunner N, Boulay V, Fojo A, Freter CE, Lippman ME & Clarke R 1993a Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Research 53 283-290.
5. Brunner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME & Clarke R 1993b MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Research 53 3229-3232.
6. Coopman P, Garcia M, Brunner N, Derocq D, Clarke R & Rochefort H 1994 Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. International Journal of Cancer 56 295-300. (doi:10.1002/ijc.2910560225)
7. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyli S, Fox MS & Leitman DC 2006 Distinct roles of unliganded estrogen receptors in transcriptional repression. Molecular Cell 21 555-564. (doi:10.1016/j.molcel. 2006.01.014)
8. Dutertre M & Smith CL 2003 Ligand-independent interactions of p160/steroid receptor coactivators and CREB-binding protein (CBP) with estrogen receptor-α: regulation by phosphorylation sites in the A/B region depends on other receptor domains. Molecular Endocrinology 17 1296-1314. (doi:10.1210/me.2001-0316)
9. Early Breast Cancer Trialists' Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 1451-1467. (doi:10.1016/S0140-6736(97)11423-4)
10. Fleming FJ, Myers E, Kelly G, Crotty TB, O'Higgins NJ, Hill AD & Young LS 2004 Expression of SRC-1, AIB1 and PEA3 in HER2 mediated endocrine resistant breast cancer: a predictive role for SRC-1. Journal of Clinical Pathology 57 1069-1074. (doi:10.1136/jcp.2004.016733)
11. Karmakar S, Foster EA & Smith CL 2009 Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-a transcriptional activity. Endocrinology 150 1588-1596. (doi:10.1210/en.2008-1001)
12. Kishimoto H, Wang Z, Bhat-Nakshatri P, Chang D, Clarke R & Nakshatri H 2005 The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. Carcinogenesis 26 1706-1715. (doi:10.1093/carcin/bgi137)
13. Labhart P, Karmakar S, Salicru EM, Egan BS, Alexiadis V, O'Malley BW& Smith CL 2005 Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. PNAS 102 1339-1344. (doi:10.1073/pnas.0409578102)
14. Lahusen T, Fereshteh M, Oh A, Wellstein A & Riegel AT 2007 Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Research 67 7256-7265. (doi:10.1158/0008-5472.CAN-07-1013)
15. Li X, Wong J, Tsai SY, Tsai M-J & O'Malley BW 2003 Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Molecular and Cellular Biology 23 3763-3773. (doi:10.1128/MCB.23.11.3763-3773.2003)
16. List H-J, Lauritsen KJ, Reiter R, Powers C, Wellstein A & Riegel AT 2001 Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. Journal of Biological Chemistry 276 23763-23768. (doi:10.1074/jbc.M102397200)
17. Louie MC, Zou JX, Rabinovich A & Chen H-W 2004 ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Molecular and Cellular Biology 24 5157-5171. (doi:10.1128/MCB.24.12.5157-5171.2004)
18. Louie MC, Revenko AS, Zou JX, Yao J & Chen H-W 2006 Direct control of cell cycle gene expression by protooncogene product ACTR, and its autoregulation underlies its transforming activity. Molecular and Cellular Biology 26 3810-3823. (doi:10.1128/MCB.26.10.3810-3823.2006)
19. Morrison AJ, Herrick RE, Heinsohn EC, Schiff R & Osborne CK 2003 Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. Molecular Endocrinology 17 1543-1554. (doi:10.1210/me.2001-0144)
20. Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M & Watson PH 2009 The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo. Journal of Steroid Biochemistry and Molecular Biology 114 90-95. (doi:10.1016/j.jsbmb.2009.01.017)
21. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, Hill AD & Young LS 2004 Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. British Journal of Cancer 91 1687-1693. (doi:10.1038/sj.bjc.6602156)
22. Naughton C, Macleod K, Kuske B, Clarke R, Cameron DA & Langdon SP 2007 Progressive loss of estrogen receptor a (ERa) cofactor recruitment in endocrine resistance. Molecular Endocrinology 21 2615-2626. (doi:10.1210/me. 2007-0110)
23. Nawaz Z, Lonard DM, Smith CL, Lev-Lehman E, Tsai SY, Tsai M-J & O'Malley BW 1999 The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Molecular and Cellular Biology 19 1182-1189.
24. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson J-Å 2001 Mechanisms of estrogen action. Physiological Reviews 81 1535-1565.
25. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM & Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 95 353-361. (doi:10.1093/jnci/95.5. 353)
26. Peterson TJ, Karmakar S, Pace MC, Gao T & Smith CL 2007 The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor-a transcriptional activity. Molecular and Cellular Biology 27 5933-5948. (doi:10.1128/MCB.00237-07)
27. Qin L, Liu Z, Chen H & Xu J 2009 The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Research 69 3819-3827. (doi:10.1158/0008-5472.CAN-08-4389)
28. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD & Young LS 2009 Coassociation of estrogen receptor and p160 proteins predicts resistance to endocrine treatment: SRC-1 is an independent predictor of breast cancer recurrence. Clinical Cancer Research 15 2098-2106. (doi:10.1158/1078-0432.CCR-08-1649)
29. Rogatsky I, Luecke HF, Leitman DC & Yamamoto KR 2002 Alternate surfaces of transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and repression contexts. PNAS 99 16701-16706. (doi:10.1073/pnas.262671599)
30. Sarvilinna N, Eronen H, Miettinen S, Vienonen A & Ylikomi T 2006 Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells. International Journal of Cancer 118 832-840. (doi:10.1002/ijc.21431)
31. Shang Y & Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295 2465-2468. (doi:10.1126/science.1068537)
32. Smith CL, Nawaz Z & O'Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Molecular Endocrinology 11 657-666. (doi:10.1210/me.11.6. 657)
33. Su Q, Hu S, Gao H, Ma R, Yang Q, Pan Z, Wang T & Li F 2008 Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology 75 159-168. (doi:10.1159/000159267)
34. Torres-Arzayus MI, de Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR & Brown M 2004 High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6 263-274. (doi:10.1016/j.ccr.2004.06.027)
35. Wang S, Yuan Y, Liao L, Kuang S-Q, Tien JC-Y, O'Malley BW & Xu J 2009 Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. PNAS 106 151-156. (doi:10.1073/pnas.0808703105)
36. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang S-M, Subramanian S, McKinerney E et al. 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Molecular Endocrinology 12 1605-1618. (doi:10.1210/me.12.10.1605)
37. Xu J & Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Molecular Endocrinology 17 1681-1692. (doi:10.1210/me.2003-0116)
38. Xu J, Wu RC & O'Malley BW 2009 Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nature Reviews. Cancer 9 615-630. (doi:10.1038/nrc2695)
39. Zheng FF, Wu R-C, Smith CL & O'Malley BW 2005 Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor. Molecular and Cellular Biology 25 8273-8284. (doi:10.1128/MCB.25.18.8273-8284.2005)